Literature DB >> 12406507

A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.

Pramod N Nehete1, Eric M Vela, M M Hossain, Asis K Sarkar, Nouara Yahi, Jacques Fantini, K Jagannadha Sastry.   

Abstract

The V3-loop region in the envelope protein gp120 of HIV is critical for viral infection, but its interaction with the target cells is not clear. Using synthetic peptides, representing linear V3 sequences as reagents, we obtained evidence to show inhibition of infection by both T-cell- and macrophage-tropic strains of human immunodeficiency virus type 1 (HIV-1) (X4 and R5, respectively), without interfering with gp120-CD4 interaction, by the V3 peptides through binding to host cell membrane glycosphingolipids (GSL). Synthetic peptides mimicking the central 15-21 amino acid sequence of the V3-loop region in both X4 and R5 strains of HIV-1 competed with and blocked the entry of both types of HIV isolates. These HIV-inhibitory V3 peptides exhibited specific binding to target cells that was not competed by antibodies to either the primary receptor CD4 or the co-receptors CXCR-4 and CCR5. However, R15K, the V3 peptide from HIV-1 IIIB gp120 exhibited specific binding to three distinct cell surface GSL: GM3, Gb3, and GalCer. Further, R15K inhibited GSL binding of gp120 from both HIV-1 IIIB (X4, Gb3-binding strain) and HIV-1 89.6 (X4R5, GM3-binding strain). Together, these results suggest a critical V3-mediated post-CD4-binding event involving cell surface GSL binding represented by the HIV-inhibitory V3 peptides, that is common for the entry of diverse HIV-1 strains and may be targeted for the development of novel HIV therapeutics aimed at blocking viral entry.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406507     DOI: 10.1016/s0166-3542(02)00130-4

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  15 in total

Review 1.  Role of glycosphingolipids in dendritic cell-mediated HIV-1 trans-infection.

Authors:  Wendy Blay Puryear; Suryaram Gummuluru
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 2.  Roles for biological membranes in regulating human immunodeficiency virus replication and progress in the development of HIV therapeutics that target lipid metabolism.

Authors:  Norman J Haughey; Luis B Tovar-y-Romo; Veera Venkata Ratnam Bandaru
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-29       Impact factor: 4.147

3.  Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.

Authors:  S Moses Dennison; Kara M Anasti; Frederick H Jaeger; Shelley M Stewart; Justin Pollara; Pinghuang Liu; Erika L Kunz; Ruijun Zhang; Nathan Vandergrift; Sallie Permar; Guido Ferrari; Georgia D Tomaras; Mattia Bonsignori; Nelson L Michael; Jerome H Kim; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Hua-Xin Liao; Barton F Haynes; S Munir Alam
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4.  Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.

Authors:  Andrew Rosa Borges; Lindsay Wieczorek; Benitra Johnson; Alan J Benesi; Bruce K Brown; Richard D Kensinger; Fred C Krebs; Brian Wigdahl; Robert Blumenthal; Anu Puri; Francine E McCutchan; Deborah L Birx; Victoria R Polonis; Cara-Lynne Schengrund
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

5.  PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection.

Authors:  Timothy M Hanley; Wendy Blay Puryear; Suryaram Gummuluru; Gregory A Viglianti
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

6.  Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes.

Authors:  Mikhail A Zhukovsky; Stéphane Basmaciogullari; Beatriz Pacheco; Liping Wang; Navid Madani; Hillel Haim; Joseph Sodroski
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

Review 7.  Prospects for antisense peptide nucleic acid (PNA) therapies for HIV.

Authors:  Virendra N Pandey; Alok Upadhyay; Binay Chaubey
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

8.  Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.

Authors:  Himanshu Garg; Nicholas Francella; Kurissery A Tony; Line A Augustine; Joseph J Barchi; Jacques Fantini; Anu Puri; David R Mootoo; Robert Blumenthal
Journal:  Antiviral Res       Date:  2008-05-19       Impact factor: 5.970

9.  Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein.

Authors:  Magnus Sundstrom; Rebecca L White; Aymeric de Parseval; K Jagannadha Sastry; Garrett Morris; Chris K Grant; John H Elder
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

Review 10.  The role of glycosphingolipids in HIV signaling, entry and pathogenesis.

Authors:  Mathias Viard; Isabella Parolini; Satinder S Rawat; Katia Fecchi; Massimo Sargiacomo; Anu Puri; Robert Blumenthal
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.